MIRM — Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Product Sales: $176 million for Q2 2026, up from $128 million in Q2 2025.
• Full-Year Sales Guidance: Increased to $680 million - $700 million for 2026.
• Cash Position: Cash equivalents and investments rose to $561 million from $391 million at the beginning of the year.
• Operating Expenses: Total operating expenses were $290 million, with $76 million allocated to R&D and $66 million to SG&A.
• Cash Contribution Margin: High-50s percentage, a 5 percentage point improvement year-over-year.

2. Strategic Updates and Business Highlights:

• Commercial Performance: Strong execution across the portfolio, particularly with Livmarli, which generated $129 million in sales, supported by new patient starts and increased awareness of PFIC.
• Pipeline Progress:
  • Zilurgisertib for FOP is on track for a potential launch in Q4 2026, with a PDUFA date next month.
  • Volixibat for PSC received breakthrough therapy designation, with a pivotal study (VISTA) showing significant results. However, the FDA has recommended a Phase 3 study before NDA submission, now targeted for H1 2027.
  • Ongoing studies for volovitug and Livmarli are expected to yield important data in the upcoming quarters.

3. Forward Guidance and Outlook:

• Anticipated continued growth in net product sales, with Livmarli projected to reach over $1 billion in peak revenue potential.
• Upcoming clinical milestones include top-line results from the AZURE-1 and AZURE-4 studies, as well as the EXPAND study for Livmarli.
• The company is positioned for strategic investments in potential launches and business development opportunities.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Delays: The FDA's recommendation for an additional Phase 3 study for volixibat has delayed the NDA submission timeline to H1 2027, raising concerns about potential revenue impacts from PSC.
• FDA Interactions: The need for further discussions with a new FDA team may complicate the regulatory pathway and extend timelines.
• Market Risks: The competitive landscape and the need for ongoing education about rare diseases may present challenges in expanding the patient base.

5. Notable Q&A Insights:

• Management clarified that the VISTA study data is robust, and they are confident in addressing FDA concerns without needing a Phase 3 trial.
• The FDA's request for additional studies appears to be more about familiarization with the data rather than specific safety or efficacy concerns.
• The company is actively preparing for the launch of Zilurgisertib and is confident in its commercial strategy, leveraging existing teams and relationships with specialized centers.
• Management emphasized that pruritus remains an approvable endpoint, and they are open to exploring post-marketing registry studies rather than a confirmatory Phase 3.

Overall, Mirum Pharmaceuticals demonstrated strong financial performance and strategic progress, despite facing regulatory hurdles that could impact timelines and revenue projections.